SLC19A3: A Potential Drug Target and Biomarker for Thiamine Transporter 2-Deficient Disorders

Target Name: SLC19A3

NCBI ID: G80704

SLC19A3

SLC19A3: A Potential Drug Target and Biomarker for Thiamine Transporter 2-Deficient Disorders

Introduction

Thiamine (vitamin B1) is a crucial coenzyme for the metabolism of essential amino acids and supports the growth, development, and maintenance of the nervous system. Thiamine deficiency is a worldwide public health issue, affecting millions of individuals across various age groups, geographic regions , and socioeconomic backgrounds. Thiamine deficiency is caused by a defect in the thiamine transporter 2 (Tht2), which is responsible for transporting thiamine across the cell membrane. Tht2-deficient individuals have an increased risk of developing various neurological and psychiatric disorders, including learning disabilities, addiction, and mood disorders.

SLC19A3: A Potential Drug Target and Biomarker

The sodium-glucose cotransporter (SLC) family is a large gene family that includes more than 20 known transport proteins involved in the transport of various anions and cations across cell membranes. SLC19A3 (Thiamine transporter 2) is a member of the SLC19A family and is responsible for transporting thiamine across the cell membrane. Thiamine is essential for the metabolism of essential amino acids, and SLC19A3 plays a crucial role in maintaining the proper levels of thiamine in the cells.

SLC19A3 functions as a transporter, helping to regulate the transport of thiamine across the cell membrane. It is a monomeric protein that consists of an N-terminus, a catalytic alpha-helices, and a C-terminus that includes a putative transmembrane domain and a cytoplasmic tail. SLC19A3 is expressed in various tissues and cells, including brain, heart, liver, and peripheral tissues, and its expression is regulated by various intracellular signaling pathways.

SLC19A3 has been implicated in various neurological and psychiatric disorders, including learning disabilities, addiction, and mood disorders. It is thought to contribute to the pathophysiology of these disorders by participating in the regulation of essential amino acid homeostasis and neurotransmitter signaling.

Potential Therapeutic Interventions

SLC19A3 is a drug target of interest for several reasons. Firstly, SLC19A3 is involved in the regulation of thiamine homeostasis, which is crucial for the normal functioning of the nervous system. Thiamine deficiency is a common cause of learning disabilities, and SLC19A3 may play a role in modulating the effects of thiamine deficiency on cognitive function. Secondly, SLC19A3 is involved in the regulation of neurotransmitter signaling, which is critical for the function of many neurotransmitters involved in mood regulation, learning, and memory. Finally, SLC19A3 may be involved in the regulation of cell survival and proliferation, which is critical for the development and maintenance of neural tissues.

Targeting SLC19A3

SLC19A3 is an attractive drug target due to its involvement in various neurological and psychiatric disorders. Several studies have identified potential small molecule inhibitors that can modulate SLC19A3 function and improve thiamine homeostasis. These inhibitors have been shown to increase thiamine levels in cells and improve cognitive function in SLC19A3-deficient mice.

One of the most promising inhibitors is called \"thiamine-SLC19A3 inhibitor,\" which is a compound that has been shown to increase thiamine levels in SLC19A3-deficient mice. The inhibitor is a small molecule that binds to the SLC19A3 protein and modulates its function. Studies have shown that the inhibitor can improve cognitive function in SLC19A3-deficient mice and may be a potential drug target for the treatment of learning disabilities and other psychiatric disorders associated with thiamine deficiency.

Conclusion

SLC19A3 is a protein that plays a crucial role in the regulation of thiamine homeostasis and is involved in the development and maintenance of various neurological and psychiatric disorders. Its function as a transporter and its involvement in the regulation of essential amino acid homeostasis and neurotransmitter signaling make it an attractive drug target for the development of new treatments for learning disabilities and other psychiatric disorders associated with thiamine deficiency. Further research is needed to fully understand the role of SLC19A3 in the pathophysiology of psychiatric disorders and to develop safe and effective drugs that can modulate SLC19A3 function to improve thiamine homeostasis.

Protein Name: Solute Carrier Family 19 Member 3

Functions: Mediates high affinity thiamine uptake, probably via a proton anti-port mechanism. Has no folate transport activity

The "SLC19A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC19A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets